Comparison
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 vs 15q Overgrowth Syndrome
Clinical comparison between 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia and 15q Overgrowth Syndrome for differential diagnosis and treatment planning.
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
An inherited disorder affecting adrenal hormone production, causing cortisol deficiency and other hormonal imbalances. Features may include ambiguous genitalia, salt-wasting crises, and growth issues. Treated with lifelong hormone replacement therapy.
15q Overgrowth Syndrome
6 comparison axes
Onset
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
0-null
15q Overgrowth Syndrome
0-0
Onset patterns differ
Severity
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
severe
15q Overgrowth Syndrome
moderate
Different severity levels
Chronic
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
Chronic
15q Overgrowth Syndrome
Chronic
Differing course
Communicable
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
No
15q Overgrowth Syndrome
No
Different transmission
Body System
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
15q Overgrowth Syndrome
congenital
Same/different system
Category
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
15q Overgrowth Syndrome
genetic
Different category
Bottom line
21-hydroxylase-deficient-congenital-adrenal-hyperplasia-C2936858 and 15q-overgrowth-syndrome-C4749920 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | 15q Overgrowth Syndrome | Discriminating power |
|---|---|---|---|
| Genital development | Ambiguous genitalia may occur, particularly in genetic females. | A defining genital pattern is not established in the supplied data. | Moderate |
| Acute illness | Salt-wasting crisis may cause dehydration and shock. | No supplied evidence describes salt-wasting crises. | High |
| Growth pattern | Androgen and cortisol imbalance may alter growth and puberty. | Overgrowth is implied by the name, but features are not established here. | Moderate |
When to favor each condition
Choose 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 when
Abnormal newborn CAH screen or suspected adrenal crisis
The presentation centers on cortisol deficiency and possible salt loss.
High
Ambiguous genitalia with suspected androgen excess
This pattern is recognized in 21-hydroxylase-deficient CAH.
High
CYP21A2-related genetic confirmation
A pathogenic result supports the adrenal diagnosis.
High
Choose 15q Overgrowth Syndrome when
Documented 15q dosage abnormality with overgrowth
Chromosomal evidence would favor the named syndrome, pending clinician review.
Moderate
Congenital overgrowth without an adrenal hormone pattern
Absence of CAH biochemistry makes primary adrenal disease less likely.
Moderate
Only the syndrome label is available
The supplied description is empty, so the diagnosis is not established.
Low
How key tests differ
| Test | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | 15q Overgrowth Syndrome | Interpretation |
|---|---|---|---|
| 17-hydroxyprogesterone | Often elevated; no cutoff is supplied here. | No diagnostic expectation is established. | Interpret with clinical context and laboratory reference ranges. |
| Electrolytes and renin assessment | Salt loss with low sodium or high potassium may occur. | No characteristic electrolyte pattern is supplied. | Abnormal results suggest adrenal imbalance but are not a chromosomal diagnosis. |
| Genetic or chromosomal testing | CYP21A2 testing may confirm CAH. | A 15q copy-number study would be relevant; none is supplied. | Test choice should follow the suspected mechanism. |
Prognosis comparison
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
- Outcome
- Chronic condition whose outcome depends on recognition and endocrine care; mortality is not stated.
- Factors
- Salt-wasting severity, treatment adherence, and growth or puberty management.
15q Overgrowth Syndrome
- Outcome
- Prognosis is not established because the source description is empty.
- Factors
- Specific 15q change and associated findings require clinician interpretation.
Time frame: Both are described as chronic, but the 15q course is not established.
Confirmed diagnosis, complications, and individualized specialist follow-up.
Complications comparison
| Complication | Presentation |
|---|---|
| Adrenal crisis | Possible, especially in salt-wasting disease. Not established from supplied evidence. Urgent clinician assessment is required for suspected crisis. |
| Growth disturbance | Early growth changes or reduced adult height may occur. Overgrowth is suggested only by the concept name. Exact growth outcomes are not quantified here. |
| Reproductive or developmental effects | Puberty and fertility may be affected. Developmental effects are not described in the source. Individual evaluation is needed; do not infer a fixed outcome. |
Patient education highlights
- HighEmergency symptoms
For known or suspected CAH, seek urgent care for vomiting, lethargy, dehydration, or collapse.
- HighTreatment changes
CAH commonly requires lifelong specialist hormone care; doses are not specified here.
- MediumGenetic counseling
Both concepts are genetic or congenital, but testing should be individualized.